非小细胞肺癌对化疗免疫疗法的耐药性。
Resistance to chemoimmunotherapy in non-small-cell lung cancer.
作者信息
Hochmair Maximilian Johannes
机构信息
Respiratory Oncology Unit, Vienna North Hospital - Klinik Floridsdorf, Vienna 1210, Austria.
出版信息
Cancer Drug Resist. 2020 Jul 12;3(3):445-453. doi: 10.20517/cdr.2020.09. eCollection 2020.
Abstract
Recent clinical trials evaluating the combination of chemotherapy with immune checkpoint inhibition for the primary treatment of lung cancer showed increased progression-free and overall survival compared with chemotherapy alone. However, the combination of these two modalities is less than additive and the mechanisms of resistance to this therapeutic intervention are discussed here. So far, the conventional biomarkers for immunotherapy, namely programmed death-ligand 1 expression or tumor mutational burden are poor predictors of the efficacy of immunochemotherapy, and the optimal sequence of chemotherapy and immunotherapy has yet to be defined.
摘要
近期评估化疗联合免疫检查点抑制剂用于肺癌一线治疗的临床试验表明，与单纯化疗相比，无进展生存期和总生存期均有所延长。然而，这两种治疗方式的联合效果并非简单相加，本文将探讨对这种治疗干预产生耐药的机制。到目前为止，免疫治疗的传统生物标志物，即程序性死亡配体1表达或肿瘤突变负荷，对免疫化疗疗效的预测效果不佳，化疗和免疫治疗的最佳顺序尚未明确。
相似文献
1
Resistance to chemoimmunotherapy in non-small-cell lung cancer.
Cancer Drug Resist. 2020 Jul 12;3(3):445-453. doi: 10.20517/cdr.2020.09. eCollection 2020.
2
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
3
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Cancer. 2021 Mar 1;127(5):709-719. doi: 10.1002/cncr.33269. Epub 2020 Oct 29.
4
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.
Transl Lung Cancer Res. 2022 Feb;11(2):277-294. doi: 10.21037/tlcr-22-75.
5
Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
JAMA Netw Open. 2021 May 3;4(5):e2111113. doi: 10.1001/jamanetworkopen.2021.11113.
6
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
7
Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Front Immunol. 2021 Apr 13;12:646874. doi: 10.3389/fimmu.2021.646874. eCollection 2021.
8
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.
9
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.
10
The next generation of immunotherapy: keeping lung cancer in check.
J Hematol Oncol. 2017 Apr 24;10(1):87. doi: 10.1186/s13045-017-0456-5.
引用本文的文献
1
Vismodegib Potentiates Marine Antimicrobial Peptide Tilapia Piscidin 4-Induced Cytotoxicity in Human Non-Small Cell Lung Cancer Cells.
Probiotics Antimicrob Proteins. 2024 May 14. doi: 10.1007/s12602-024-10282-8.
2
Identifying the Multitarget Pharmacological Mechanism of Action of Genistein on Lung Cancer by Integrating Network Pharmacology and Molecular Dynamic Simulation.
Molecules. 2024 Apr 23;29(9):1913. doi: 10.3390/molecules29091913.
3
Vascular normalization and immunotherapy: Spawning a virtuous cycle.
Front Oncol. 2022 Oct 6;12:1002957. doi: 10.3389/fonc.2022.1002957. eCollection 2022.
4
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer.
Invest New Drugs. 2022 Apr;40(2):215-223. doi: 10.1007/s10637-021-01181-8. Epub 2021 Oct 1.
本文引用的文献
1
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Melanoma Res. 2020 Aug;30(4):364-375. doi: 10.1097/CMR.0000000000000669.
2
Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Cancer Med. 2020 Mar;9(5):1683-1693. doi: 10.1002/cam4.2793. Epub 2020 Jan 16.
3
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419890020. doi: 10.1177/1534735419890020.
4
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations.
Expert Rev Respir Med. 2020 Feb;14(2):125-136. doi: 10.1080/17476348.2020.1701439. Epub 2019 Dec 12.
5
Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Future Sci OA. 2019 Sep 25;5(9):FSO421. doi: 10.2144/fsoa-2019-0081.
6
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.
7
Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer.
Sci Rep. 2019 Sep 17;9(1):13451. doi: 10.1038/s41598-019-49943-y.
8
Effect and biomarker of Nivolumab for non-small-cell lung cancer.
Biomed Pharmacother. 2019 Sep;117:109199. doi: 10.1016/j.biopha.2019.109199. Epub 2019 Jul 5.
9
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.
10
The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?
Immunotherapy. 2019 Jul;11(10):913-920. doi: 10.2217/imt-2019-0014. Epub 2019 Jun 12.
Zotero 插件